Get the Stockscreener App
43.57
1.54%
-0.68
After Hours:
43.57
Revolution Medicines Inc stock is traded at $43.57, with a volume of 1.78M.
It is down -1.54% in the last 24 hours and down -0.62% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$44.25
Open:
$44.21
24h Volume:
1.78M
Relative Volume:
1.13
Market Cap:
$8.05B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-11.90
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
+1.16%
1M Performance:
-0.62%
6M Performance:
+0.65%
1Y Performance:
+46.01%
1-Day Range:
$43.52
$44.67
1-Week Range:
$41.62
$44.68
52-Week Range:
$28.43
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
43.57 | 8.05B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
An analyst sees good growth prospects for Revolution Medicines Inc (RVMD) - SETE News
Revolution Medicines, Inc. (NASDAQ:RVMD) Stake Lifted by KBC Group NV - Defense World
Revolution Medicines' SWOT analysis: stock shows promise amid cancer treatment advances - MSN
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates - MSN
Are Investors Undervaluing Revolution Medicines, Inc. (NASDAQ:RVMD) By 49%? - Simply Wall St
China Universal Asset Management Co. Ltd. Grows Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Is Revolution Medicines, Inc. (NASDAQ:RVMD) Trading At A 49% Discount? - Yahoo Finance
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Average Target Price from Brokerages - Defense World
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
RAS Cancer Breakthrough? Revolution Medicines CEO Takes Center Stage at Major Biotech Event - StockTitan
Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) - Seeking Alpha
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Average Target Price from Analysts - MarketBeat
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - MSN
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials By Investing.com - Investing.com South Africa
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - Investing.com Canada
Revolution Medicines general counsel Jeff Cislini sells $97,443 in stock - MSN
Revolution Medicines general counsel Jeff Cislini sells $97,443 in stock By Investing.com - Investing.com Australia
Sandy Cove Advisors LLC Acquires Shares of 42,008 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts? - Insider Monkey
Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. - Marketscreener.com
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6%Should You Sell? - MarketBeat
(RVMD) Trading Advice - Stock Traders Daily
Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, UBS Group Analyst Says - Defense World
UBS Group Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Principal Financial Group Inc. Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $65.82 - Defense World
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):